CN111505272A - Excrement diluent and application thereof - Google Patents
Excrement diluent and application thereof Download PDFInfo
- Publication number
- CN111505272A CN111505272A CN202010311488.5A CN202010311488A CN111505272A CN 111505272 A CN111505272 A CN 111505272A CN 202010311488 A CN202010311488 A CN 202010311488A CN 111505272 A CN111505272 A CN 111505272A
- Authority
- CN
- China
- Prior art keywords
- diluent
- percent
- mass
- sample
- stool
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003085 diluting agent Substances 0.000 title claims abstract description 67
- 238000001514 detection method Methods 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000012153 distilled water Substances 0.000 claims abstract description 12
- 239000000022 bacteriostatic agent Substances 0.000 claims abstract description 10
- 239000004094 surface-active agent Substances 0.000 claims abstract description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims abstract description 6
- 229940098773 bovine serum albumin Drugs 0.000 claims abstract description 6
- 210000003608 fece Anatomy 0.000 claims description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- 239000012928 buffer substance Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 238000010790 dilution Methods 0.000 claims description 14
- 239000012895 dilution Substances 0.000 claims description 14
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical group [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 13
- 235000010234 sodium benzoate Nutrition 0.000 claims description 13
- 239000004299 sodium benzoate Substances 0.000 claims description 13
- 241000283690 Bos taurus Species 0.000 claims description 12
- 230000002550 fecal effect Effects 0.000 claims description 12
- 108010088751 Albumins Proteins 0.000 claims description 11
- 102000009027 Albumins Human genes 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 9
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 9
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- NQSJDHNNJIQPNW-UHFFFAOYSA-K trisodium;trichloride Chemical compound [Na+].[Na+].[Na+].[Cl-].[Cl-].[Cl-] NQSJDHNNJIQPNW-UHFFFAOYSA-K 0.000 claims description 6
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 5
- BUCIWTBCUUHRHZ-UHFFFAOYSA-K potassium;disodium;dihydrogen phosphate;hydrogen phosphate Chemical compound [Na+].[Na+].[K+].OP(O)([O-])=O.OP([O-])([O-])=O BUCIWTBCUUHRHZ-UHFFFAOYSA-K 0.000 claims description 4
- 239000007983 Tris buffer Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims 3
- 238000006243 chemical reaction Methods 0.000 abstract description 13
- 238000001179 sorption measurement Methods 0.000 abstract description 8
- 238000004458 analytical method Methods 0.000 abstract description 4
- 230000001580 bacterial effect Effects 0.000 abstract description 4
- 239000007853 buffer solution Substances 0.000 abstract description 4
- 238000003317 immunochromatography Methods 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 12
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 230000006870 function Effects 0.000 description 4
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008722 morphological abnormality Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention belongs to the technical field of sample diluent preparation, and relates to a stool diluent and application thereof. The excrement diluent comprises the following components in percentage by mass: 5 to 10 percent of buffer solution, 0.02 to 0.06 percent of surfactant, 0.005 to 0.02 percent of bacteriostatic agent, 0.02 to 0.06 percent of bovine serum albumin and the balance of distilled water. The excrement diluent provided by the invention is low in cost, can effectively improve the stability of a diluent system, prevents bacterial pollution, does not influence the components of a sample, has no interference on a detection result, can be better used for immunochromatography rapid detection and analysis, avoids the occurrence of nonspecific adsorption reaction of the sample, and ensures the repeatability and accuracy of the detection result.
Description
Technical Field
The invention relates to the technical field of sample diluent preparation, in particular to a stool diluent and application thereof.
Background
Human feces mainly comprise undigested food, food which is not absorbed after digestion, secretion of a digestive system, digestive tract mucosa castoff, microorganisms, parasites and the like, and the human feces are detected to obtain information of digestive system functions, pathological changes, microorganism infection, parasite infection and the like of a detected person. When testing and assaying the feces, the feces usually needs to be diluted by a feces diluent.
Most of the existing excrement diluent is tap water, deionized water and normal saline, the tap water and the deionized water cannot protect the form of visible components in excrement, and the change of the form of the components with diagnostic significance can influence the judgment of the routine diagnostic result of the excrement; in addition, tap water and deionized water are used as diluents, and the positive detection rate is low when the diluents are used for an immunochromatography fecal occult blood test. The normal saline is generally used for manual detection, and the normal saline is not subjected to bacteriostatic treatment, so that microorganisms are bred in the pipeline if the normal saline is used in a matched excrement analysis workstation, and the pipeline is possibly blocked due to crystallization after long-term use, so that the normal saline is not suitable for instruments. Therefore, the conventional use of water or physiological saline as a stool diluent is disadvantageous to the stability of the reaction system and is easily contaminated, thereby affecting the judgment of the result. Moreover, if only the buffer solution and the bacteriostatic agent are added into the diluent, the specific adsorption reaction of the sample cannot be inhibited, and the judgment of the detection result is also affected. Therefore, providing a stool diluent that does not affect the form of sample components and can avoid non-specific adsorption reactions of the sample is important for obtaining information such as digestive system function, pathological changes, microbial and parasitic infections of a detector in stool detection and assay.
Disclosure of Invention
In view of the above, the invention provides the stool diluent and the application thereof, and the stool diluent can effectively improve the stability of a diluent system, does not affect the components of a sample, avoids the occurrence of nonspecific adsorption reaction of the sample, and ensures the repeatability and the accuracy of a detection result.
In order to solve the technical problems, the invention provides the following technical scheme:
the invention provides a feces diluent which comprises the following components in percentage by mass: 5 to 10 percent of buffer substance, 0.02 to 0.06 percent of surfactant, 0.005 to 0.02 percent of bacteriostatic agent, 0.02 to 0.06 percent of bovine serum albumin and the balance of distilled water.
Preferably, the buffer substance is a disodium hydrogen phosphate-potassium dihydrogen phosphate mixture or a tris-sodium chloride mixture.
More preferably, when the buffer substance is a mixture of disodium hydrogen phosphate and potassium dihydrogen phosphate, the content of disodium hydrogen phosphate in the feces diluent is 5 to 7% by mass, and the content of potassium dihydrogen phosphate in the feces diluent is 0.5 to 1.5% by mass.
More preferably, when the buffer substance is a tris-sodium chloride mixture, the tris is 8 to 10% by mass in the feces diluent and the sodium chloride is 0.5 to 0.8% by mass in the feces diluent.
Preferably, the surfactant is Tween-80.
More preferably, the mass percentage of the Tween-80 in the feces diluent is 0.05%.
Preferably, the bacteriostatic agent is sodium benzoate.
More preferably, the sodium benzoate accounts for 0.01 percent of the mass of the excrement diluent.
Preferably, the bovine blood albumin is 0.05% by mass of the feces diluent.
The invention also provides application of the excrement diluent in excrement detection assay.
Compared with the prior art, the invention has the following beneficial effects:
the excrement diluent comprises a buffer substance, a surfactant, a bacteriostatic agent and bovine serum albumin, wherein the surfactant can provide a good hydrophilic environment for sample reaction, so that a sample can be fully dissolved, the buffer solution can improve the ionic environment of the sample, and the buffer solution and the bovine serum albumin added at the same time can prevent the sample from generating nonspecific adsorption reaction and have a certain pH buffering effect on the sample. The excrement diluent provided by the invention is low in cost, can effectively improve the stability of a diluent system, prevents bacterial pollution, does not influence the components of a sample, has no interference on a detection result, can be better used for immunochromatography rapid detection and analysis, avoids the occurrence of nonspecific adsorption reaction of the sample, and ensures the repeatability and accuracy of the detection result.
Detailed Description
The invention provides a feces diluent which comprises the following components in percentage by mass: 5 to 10 percent of buffer substance, 0.02 to 0.06 percent of surfactant, 0.005 to 0.02 percent of bacteriostatic agent, 0.02 to 0.06 percent of bovine serum albumin and the balance of distilled water.
In the present invention, the buffer substance is preferably a disodium hydrogen phosphate-potassium dihydrogen phosphate mixture or a tris-sodium chloride mixture. The content of the buffer substance in percentage by mass is preferably 5% -10%, and more preferably 6% -8%. In the invention, the buffer substance mainly functions to improve the ionic environment of the sample and provide a stable pH environment, thereby providing a stable reaction system for the sample.
In the present invention, when the buffer substance is a disodium hydrogen phosphate-potassium dihydrogen phosphate mixture, the content of disodium hydrogen phosphate in the feces diluent is preferably 5% to 7% by mass, and more preferably 6% by mass; the content of monopotassium phosphate in the feces diluent is preferably 0.5-1.5% by mass, and more preferably 1% by mass. When the buffer substance is a tris-sodium chloride mixture, the mass percentage content of tris in the feces diluent is preferably 8% -10%, more preferably 9%; the mass percentage content of the sodium chloride in the feces diluent is preferably 0.5-0.8%, and more preferably 0.6%. The sources of the disodium hydrogen phosphate, the potassium dihydrogen phosphate, the tris (hydroxymethyl) aminomethane and the sodium chloride are not particularly limited in the present invention, and any commercially available product that is conventional in the art may be used.
In the invention, the surfactant is preferably Tween-80. The mass percentage content of the surfactant in the feces diluent is preferably 0.02-0.06%, and more preferably 0.05%. In the invention, the Tween-80 has excellent water solubility and mainly plays a role in providing a good hydrophilic environment for sample reaction so as to enable the sample to be fully dissolved. The source of the Tween-80 is not particularly limited in the invention, and the Tween-80 can be prepared from conventional commercial products in the field.
In the invention, the bacteriostatic agent is preferably sodium benzoate. The mass percentage content of the sodium benzoate in the excrement diluent is preferably 0.005% -0.02%, and more preferably 0.01%. In the invention, the bacteriostatic agent has the functions of preventing a reaction system from being polluted by bacteria and prolonging the preservation time of the diluent. The source of the sodium benzoate is not particularly limited in the invention, and the conventional commercial products in the field can be adopted.
In the invention, the bovine blood albumin is preferably newborn bovine blood serum. The bovine blood albumin is preferably 0.02 to 0.06 percent by mass, and more preferably 0.05 percent by mass in the feces diluent. In the invention, the bovine blood albumin can not only prevent the sample from generating nonspecific adsorption reaction, but also play a certain role in pH buffering for the sample. The source of the present invention is not particularly limited, and any commercially available product conventionally used in the art may be used.
In the present invention, the distilled water is used as a solvent. The addition amount of the distilled water is not particularly limited, and the amount can be specifically adjusted according to the total amount of the excrement diluent required by preparation and the mass percentage of each component.
The invention also provides application of the excrement diluent in excrement detection assay. The excrement diluent disclosed by the invention is used for diluting excrement and detecting and testing the diluted excrement to obtain excrement related information.
In order to further illustrate the present invention, the following embodiments are described in detail, but they should not be construed as limiting the scope of the present invention.
In this example, other materials or instruments are commercially available, and the source thereof is not limited in the present invention.
Example 1
The components are as follows by mass percent: 6 percent of disodium hydrogen phosphate, 1 percent of monopotassium phosphate, 1 percent of Tween-800.05, 0.01 percent of sodium benzoate and 0.05 percent of bovine blood albumin, and dissolving the mixture in distilled water to prepare the excrement diluent.
Example 2
The components are as follows by mass percent: 7 percent of disodium hydrogen phosphate, 0.5 percent of monopotassium phosphate, 0.01 percent of Tween-800.05 percent of sodium benzoate and 0.05 percent of bovine blood albumin, and dissolving the components in distilled water to prepare the excrement diluent.
Example 3
The components are as follows by mass percent: 7 percent of disodium hydrogen phosphate, 1.5 percent of monopotassium phosphate, 1.78 percent of Tween-800.05 percent, 0.01 percent of sodium benzoate and 0.05 percent of bovine blood albumin, and dissolving the mixture in distilled water to prepare the excrement diluent.
Example 4
The components are as follows by mass percent: 8% of trihydroxymethyl aminomethane, 0.5% of sodium chloride, 0.78% of Tween-800.05%, 0.01% of sodium benzoate and 0.05% of bovine blood albumin, and dissolving in distilled water to prepare the feces diluent.
Example 5
The components are as follows by mass percent: 9 percent of trihydroxymethyl aminomethane, 0.6 percent of sodium chloride, 0.01 percent of Tween-800.05 percent of sodium benzoate and 0.05 percent of bovine blood albumin are dissolved in distilled water to prepare the excrement diluent.
Example 6
The components are as follows by mass percent: 10 percent of trihydroxymethyl aminomethane, 0.8 percent of sodium chloride, 0.01 percent of Tween-800.05 percent of sodium benzoate and 0.05 percent of bovine blood albumin are dissolved in distilled water to prepare the excrement diluent.
Example 7
1. Erythrocyte deformation and rupture rate measurement
The fecal diluent 10m L prepared in the above examples 1-6 was put into a test tube, 50 μ L of red blood cell sample was added to the test tube, mixed, 2-3 drops of the sample was dropped into a cell counting plate, mixed, the total amount and morphological abnormality number of red blood cells in the counting frame of the cell counting plate were counted using a biological microscope, and the deformation rate and rupture rate of red blood cells were calculated according to the following formulas, and the results are shown in table 1.
Erythrocyte morphosis rate (%) -abnormal morphology erythrocyte number ÷ total erythrocyte number × 100%
TABLE 1 Effect of stool dilution on erythrocyte deformation and rupture Rate
| Numbering | Percent deformation (%) | Percentage of rupture (%) |
| Example 1 | 1 | 0 |
| Example 2 | 2 | 1 |
| Example 3 | 2 | 0 |
| Example 4 | 1 | 1 |
| Example 5 | 1 | 0 |
| Example 6 | 1 | 1 |
The above results show that: the fecal dilutions of examples 1-6 had low erythrocyte deformation rates, and were able to maintain erythrocyte morphology well, without affecting the composition of the sample itself, and without interfering with the assay results.
2. Stability test
The stool dilutions 10m L prepared in the above examples 1-6 were used as experimental group and 10m L0.9.9% physiological saline as control group, and the experimental group and the control group were placed in the same indoor environment for three months, and the conditions of the experimental group and the control group were observed every month, and the experimental results were recorded as shown in table 2:
TABLE 2 contamination of the fecal dilutions over time
| Numbering | One month | Two months old | Three months old |
| Example 1 | Clear and transparent without foreign matter | Clear and transparent without foreign matter | Clear and transparent without foreign matter |
| Example 2 | Clear and transparent without foreign matter | Clear and transparent without foreign matter | Clear and transparent without foreign matter |
| Example 3 | Clear and transparent without foreign matter | Clear and transparent without foreign matter | Clear and transparent without foreign matter |
| Example 4 | Clear and transparent without foreign matter | Clear and transparent without foreign matter | Clarifying and penetratingHas no foreign matter |
| Example 5 | Clear and transparent without foreign matter | Clear and transparent without foreign matter | Clear and transparent without foreign matter |
| Example 6 | Clear and transparent without foreign matter | Clear and transparent without foreign matter | Clear and transparent without foreign matter |
| Control group | Clear and transparent without foreign matter | Slightly flocculent | Has more floccules |
From the above results, it can be seen that: the fecal diluent prepared in the examples 1-6 of the invention has no obvious change, while the normal saline control group gradually generates floccules. The excrement diluent can prevent bacterial pollution and has good stability.
3. Repeatability and accuracy testing
The stool diluent is tested by utilizing a conventional commercially available immunochromatographic test strip in the field, and the accuracy of the diluent is verified by using an automatic stool analyzer as a reference.
Taking out the immunochromatographic assay plate, and placing the immunochromatographic assay plate on a drying platform.
10 portions of each of the positive fecal sample and the negative fecal sample are diluted to be completely dissolved by the fecal diluent prepared in the above example 1, 3 to 4 drops of the sample floating on the upper layer are absorbed and added into the sample adding hole of the immunochromatographic detection plate, and the result is read after 10 minutes. At the same time, a stool analyzer was used for the control test. The following table 3 was obtained:
TABLE 3 dilution test results of different samples with stool diluent
As can be seen from the above table, the test results of the sample diluent combined with the test strip are consistent with the theoretical values, and the repeated results are consistent, which shows that the stool diluent of the invention has no interference to the test results and has repeatability. Meanwhile, the detection result of the excrement diluent combined with the test strip is consistent with that of an excrement analyzer, and the excrement diluent has good accuracy.
The embodiment shows that the excrement diluent provided by the invention is low in cost, can effectively improve the stability of a diluent system, prevents bacterial pollution, does not influence the components of a sample, has no interference on a detection result, can be better used for immunochromatography rapid detection and analysis, avoids the occurrence of nonspecific adsorption reaction of the sample, and ensures the repeatability and accuracy of the detection result.
The above description is only an embodiment of the present invention, and not intended to limit the scope of the present invention, and all modifications of equivalent structures and equivalent processes, which are made by the present specification, or directly or indirectly applied to other related technical fields, are included in the scope of the present invention.
Claims (10)
1. The excrement diluent is characterized by comprising the following components in percentage by mass: 5 to 10 percent of buffer substance, 0.02 to 0.06 percent of surfactant, 0.005 to 0.02 percent of bacteriostatic agent, 0.02 to 0.06 percent of bovine serum albumin and the balance of distilled water.
2. Faecal dilution according to claim 1, characterised in that the buffer substance is a mixture of disodium hydrogen phosphate and potassium dihydrogen phosphate or a mixture of tris-sodium chloride.
3. The stool dilution according to claim 2, wherein when the buffer substance is a disodium hydrogen phosphate-potassium dihydrogen phosphate mixture, the disodium hydrogen phosphate is present in the stool dilution in an amount of 5% to 7% by mass, and the potassium dihydrogen phosphate is present in the stool dilution in an amount of 0.5% to 1.5% by mass.
4. The diluted feces liquid according to claim 2, wherein when the buffer substance is a tris-sodium chloride mixture, tris is present in an amount of 8 to 10% by mass in the diluted feces liquid, and sodium chloride is present in an amount of 0.5 to 0.8% by mass in the diluted feces liquid.
5. The fecal diluent of claim 1 wherein the surfactant is Tween-80.
6. The fecal diluent of claim 5, characterized in that the mass percentage content of Tween-80 in the fecal diluent is 0.05%.
7. The fecal diluent of claim 1 wherein the bacteriostatic agent is sodium benzoate.
8. The stool dilution according to claim 7, wherein the sodium benzoate is present in the stool dilution in an amount of 0.01% by weight.
9. The stool dilution according to claim 1, wherein the bovine blood albumin is present in the stool dilution in an amount of 0.05% by weight.
10. Use of a stool dilution according to any one of claims 1-9 in a stool detection assay.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010311488.5A CN111505272A (en) | 2020-04-20 | 2020-04-20 | Excrement diluent and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010311488.5A CN111505272A (en) | 2020-04-20 | 2020-04-20 | Excrement diluent and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111505272A true CN111505272A (en) | 2020-08-07 |
Family
ID=71876219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010311488.5A Pending CN111505272A (en) | 2020-04-20 | 2020-04-20 | Excrement diluent and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111505272A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5094956A (en) * | 1987-02-04 | 1992-03-10 | International Immunoassay Laboratories, Inc. | Fecal sample immunoassay composition and method |
| US20010024801A1 (en) * | 1999-04-15 | 2001-09-27 | Nair Padmanabhan P. | Noninvasive detection of colorectal cancer and other gastrointestinal pathology |
| JP2007322310A (en) * | 2006-06-02 | 2007-12-13 | Nippon Kayaku Co Ltd | Method for detecting or measuring substance to be analyzed in specimen |
| CN106769289A (en) * | 2016-12-02 | 2017-05-31 | 刘鹏飞 | A kind of collocation method of fecal specimens storage liquid and application |
| CN108982199A (en) * | 2018-08-13 | 2018-12-11 | 湖南品信生物工程有限公司 | A kind of excrement dilution |
| CN109557088A (en) * | 2019-01-11 | 2019-04-02 | 四川沃文特生物技术有限公司 | A kind of reagent card for detecting excrement lactose content and the excrement lactose detection method based on this |
| CN109679769A (en) * | 2018-12-14 | 2019-04-26 | 湖南品信生物工程有限公司 | A kind of excrement cleaning solution for excrement detector |
| CN110320364A (en) * | 2018-03-30 | 2019-10-11 | 洛阳普莱柯万泰生物技术有限公司 | A kind of double antibodies sandwich gold-immunochromatographyreagent reagent for assay box, and the preparation method and application thereof |
-
2020
- 2020-04-20 CN CN202010311488.5A patent/CN111505272A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5094956A (en) * | 1987-02-04 | 1992-03-10 | International Immunoassay Laboratories, Inc. | Fecal sample immunoassay composition and method |
| US20010024801A1 (en) * | 1999-04-15 | 2001-09-27 | Nair Padmanabhan P. | Noninvasive detection of colorectal cancer and other gastrointestinal pathology |
| JP2007322310A (en) * | 2006-06-02 | 2007-12-13 | Nippon Kayaku Co Ltd | Method for detecting or measuring substance to be analyzed in specimen |
| CN106769289A (en) * | 2016-12-02 | 2017-05-31 | 刘鹏飞 | A kind of collocation method of fecal specimens storage liquid and application |
| CN110320364A (en) * | 2018-03-30 | 2019-10-11 | 洛阳普莱柯万泰生物技术有限公司 | A kind of double antibodies sandwich gold-immunochromatographyreagent reagent for assay box, and the preparation method and application thereof |
| CN108982199A (en) * | 2018-08-13 | 2018-12-11 | 湖南品信生物工程有限公司 | A kind of excrement dilution |
| CN109679769A (en) * | 2018-12-14 | 2019-04-26 | 湖南品信生物工程有限公司 | A kind of excrement cleaning solution for excrement detector |
| CN109557088A (en) * | 2019-01-11 | 2019-04-02 | 四川沃文特生物技术有限公司 | A kind of reagent card for detecting excrement lactose content and the excrement lactose detection method based on this |
Non-Patent Citations (1)
| Title |
|---|
| 吴丹等: "一种快速检测粪便中血红蛋白的胶体金方法", 《江西中医药大学学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102226805B (en) | Middle/low concentration positive quality control liquid for urine analysis | |
| JP2763635B2 (en) | Detection of diamines in biological fluids | |
| Flanagan et al. | Evaluation of four screening tests for bacteriuria in elderly people | |
| US6709868B2 (en) | Method and apparatus for measuring white blood cell count | |
| Leung et al. | False-negative biopsy urease test in bleeding ulcers caused by the buffering effects of blood | |
| CN110129406A (en) | A kind of pseudomonas aeruginosa chromogenic culture medium and the method quickly detected using it | |
| CN114859031A (en) | Universal sample diluent for immunochromatography detection and preparation method thereof | |
| Sharief et al. | Use of rapid dipstick tests to exclude urinary tract infectionin children | |
| Gasol et al. | Cytometric evidence reconciling the toxicity and usefulness of CTC as a marker of bacterial activity | |
| EP1869469B1 (en) | Rapidly detecting and quantifying viable legionella | |
| Halliday et al. | Giardia-bile salt interactions in vitro and in vivo | |
| CN111505272A (en) | Excrement diluent and application thereof | |
| CN108982199A (en) | A kind of excrement dilution | |
| Wacker et al. | The Holy Cross hepatitis outbreak: Clinical and chemical abnormalities | |
| CN101706508A (en) | Preparation method of ABO subtype detection kit | |
| Simmons | An automated method for serum bilirubin determination | |
| Thysell | Evaluation of chemical and microscopical methods for mass detection of bacteriuria | |
| EP0178501B1 (en) | Method for detection of peritoneal inflammation or infection | |
| Frazier et al. | Minimizing false positive diagnoses in newborn screening for galactosemia | |
| Mazutti et al. | Evaluation of the reagent test strips and microscopic examination of urine in the diagnosis of urinary tract infection in sows | |
| CN118706571A (en) | Diluent for fecal routine analyzer and preparation method thereof | |
| Puşcaş et al. | Micro-test system for rapid isolation and identification of Candida species in urinary tract infections | |
| Sims et al. | Serum arginino-succinate lyase:: Observations on the sensitivity and specificity of this test in the detection of minimal hepatocellular damage | |
| Agrawal et al. | Comparison of the mouse foot pad test with a Buddemeyer type radiorespirometric assay in detecting viable Mycobacterium leprae in human lesional biopsies | |
| Nakao et al. | Quantitative Assay of (1–3)-β-D-Glucan in Culture Media of Candida albicans Using the G-Test |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200807 |
|
| RJ01 | Rejection of invention patent application after publication |